- Press Releases
Ambry Genetics, a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., unveiled at the American Society of Human Genetics (ASHG) annual meeting results of a study published in JAMA Oncology that assessed the cumulative impact of paired DNA and RNA testing on detecting disease-causing germline genetic variants and resolution of variants of uncertain significance (VUS).
November 4, 2023Read More
REALM IDx, Inc., a health care company pioneering the field of integrated diagnostics, announced today that GenMineTOP Cancer Genome Profiling System ("the System") has been awarded national health coverage in Japan and will begin full commercial launch of contract testing with strategic partner, LSI Medicine Corporation (Chiyoda-ku, Tokyo; hereinafter "LSIM").
August 1, 2023Read More
ALISO VIEJO, Calif. – June 1, 2023 – REALM IDx announced today the launch of REALM Pharma Services, an end-to-end discovery, translational research, and clinical trial service for biotechnology and pharmaceutical partners. Through a strategic integration, REALM Pharma Services brings together the research arms of subsidiaries, Ambry Genetics and Invicro, to offer cutting-edge genomics, traditional and molecular pathology, and advanced imaging and spatial biology.
June 1, 2023Read More
LifeStrands Genomics and Ambry Genetics to Provide Laboratory Testing for Clinical Implementation Pilots in Phase II of Singapore’s National Precision Medicine programme
LifeStrands Genomics and Ambry Genetics have joined forces to provide clinical genetic testing services in Singapore. Together, they have been chosen to support the Clinical Implementation Pilots (CIPs) for Phase II of Singapore’s National Precision Medicine (NPM) programme through an open tender commissioned by Precision Health Research, Singapore (PRECISE) – the central entity implementing NPM.
April 19, 2023Read More
Unilabs and Ambry Sign Agreement to Enhance Genetic Testing Services for Biopharma Companies in Europe, Latin America and the Middle East
Geneva and Aliso Viejo, Calif. – January 26, 2023 – Unilabs, a leading diagnostic services provider, and Ambry Genetics (Ambry), a leader in clinical diagnostic testing and a subsidiary of REALM IDx, have entered an exclusive partnership to enhance high-quality genetic testing services for government-sponsored and biopharma companies conducting international clinical trials and research.
January 26, 2023Read More
Ambry’s New Reproductive Health Program Uses Digital Platform to Make It Easier for Patients to Access Genetic Screening Before and During Pregnancy
Ambry Genetics (Ambry), a leader in clinical diagnostic testing and a subsidiary of REALM IDx, launched a new reproductive health program that is driven by its CARE ProgramTM (Comprehensive Assessment Risk and Education), a digital platform that enhances the patient and provider experience through easier access to genetic education, testing, reporting and counseling. This end-to-end program improves family planning and prenatal care by expanding access to carrier screening and NIPT, also known as non-invasive prenatal screening (NIPS), and by helping patients make informed decisions.
October 19, 2022Read More
Ambry Genetics Publishes 43,000 Patient Study Showing Combined RNA and DNA Analysis Identifies Patients Who Are High-Risk for Cancer but Would Have Been Missed by DNA Testing Alone
Ambry Genetics, a leader in clinical diagnostic testing and a subsidiary of REALM IDx, Inc., announced today the findings of a study that showed paired RNA and DNA genetic testing, conducted at the same time, detected elusive pathogenic variants in 1 of every 950 patients that were missed by DNA testing alone.
August 30, 2022Read More
Cell Stress and Mitochondrial Dysfunction Found in Early Alzheimer’s Disease Patients, Findings Published in Science Translational Medicine
Invicro LLC (Invicro), a global, industry-leading imaging CRO, and a subsidiary of REALM IDx, Inc., today announced the publication of the paper “Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimer’s disease” in Science Translational Medicine.
August 18, 2022Read More
SOPHiA GENETICS (Nasdaq: SOPH) and REALM IDx announced today that they signed a letter of intent to collaborate in the co-development of novel genomic applications and commercialization of multi-modal applications.